Advances for the treatment of primary central nervous system lymphoma (Review)

Oncology Reports

Volumn 12, Issue 3, 2004, Pages 563-568

  Yamanaka, Ryuya ^a   Tanaka, Ryuichi ^a  

^a NIIGATA UNIVERSITY   (Japan)

Author keywords

Autologous stem cell rescue; Chemotherapy; Gene expression profile; Methotrexate; Neurotoxicity; Primary central nervous system lymphoma; Radiation therapy; Second line therapy

Indexed keywords

ANTINEOPLASTIC AGENT; METHOTREXATE;

ADULT; AGED; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL TRIAL; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NONHODGKIN LYMPHOMA; QUALITY OF LIFE; RECURRENT DISEASE; REVIEW; TIME; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; METHOTREXATE; MIDDLE AGED; QUALITY OF LIFE; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME;

EID: 7744242536     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.12.3.563     Document Type: Review

References (48)

1. Hochberg FH and Miller DC: Primary central nervous system lymphoma. J Neurosurg 68: 835-853, 1988.
2. Fine HA and Loeffler JS: Primary central nervous system lymphoma. In: The Lymphomas. Canellos GP, Lister TA and Sklar JL (eds). WB Saunders, Philadelphia, pp481-494, 1998.
3. Eby NL, Grufferman S, Flannelly CM, Schold SC Jr, Vogel FS, and Burger PC: Increasing incidence of primary brain lymphoma in the US. Cancer 62: 2461-2465, 1988.
4. Cote TR, Manns A, Hardy CR, Yellin FJ and Hartge P: Epidemiology of brain lymphoma among people with or without acquired immunodeficiency syndrome. AIDS/Cancer Study Group. J Natl Cancer Inst 88: 675-679, 1996. (Pubitemid 26152554)
5. Olson JE, Janney CA, Rao RD, Cerhan JR, Kurtin PJ, Schiff D, Kaplan RS and O'Neill BP: The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis. Cancer 95: 1504-1510, 2002.
6. Pollack IF, Lunsford LD, Flickinger JC and Dameshek HL: Prognostic factors in the diagnosis and treatment of primary central nervous system lymphoma. Cancer 63: 939-947, 1989. (Pubitemid 19063206)
7. Nelson DF, Martz KL, Bonner H, Nelson JS, Newall J, Kerman HD, Thomson JW and Murray KJ: Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 23: 9-17, 1992.
8. De Angelis LM, Yahalom J, Thaler HT and Kher U: Combined modality therapy for primary CNS lymphoma. J Clin Oncol 10: 635-643, 1992.
9. Bessell EM, Graus F, Punt JA, Firth JL, Hope DT, Moloney AJ, Lopez-Guillermo A and Villa S: Primary non-Hodgkin's lymphoma of the CNS treated with BVAM or CHOD/BVAM chemotherapy before radiotherapy. J Clin Oncol 14: 945-954, 1996. (Pubitemid 26085541)
10. Glass J, Gruber ML, Cher L and Hochberg FH: Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J Neurosurg 81: 188-195, 1994. (Pubitemid 24237996)
11. Abrey LE, DeAngelis LM and Yahalom J: Long-term survival in primary CNS lymphoma. J Clin Oncol 16: 859-863, 1998. (Pubitemid 28108717)
12. Abrey LE, Yahalom J and De Angelis LM: Treatment for primary CNS lymphoma: the next step. J Clin Oncol 18: 3144-3150, 2000.
13. Freilich RJ, Delattre JY, Monjour A and De Angelis LM: Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients. Neurology 46: 435-439, 1996. (Pubitemid 26081327)
14. Fine HA and Mayer RJ: Primary central nervous system lymphoma. Ann Intern Med 119: 1093-1104, 1993. (Pubitemid 23359924)
15. Herdinger U, Schabet M, Eichhorn M, Petersen D, Grote EH, Meyermann R and Dichgans J: Prolonged corticosteroid-induced remission in primary central nervous system lymphoma: report of a case and review of the literature. Eur Neurol 36: 241-243, 1996.
16. Harris NL, Jaffe ES, Stein H, et al: A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84: 1361-1392, 1994. (Pubitemid 24273002)
17. Nelson DF: Radiotherapy in the treatment of primary central nervous system lymphoma (PCNLS). J Neurooncol 43: 241-247, 1999.
18. Mead GM, Bleehen NM, Gregor A, et al: A Medical Research Council randomized trial in patients with primary cerebral non-Hodgkin lymphoma: cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy. Cancer 8: 1359-1370, 2000.
19. Schultz C, Scott C, Sherman W, et al: Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine and dexamethasone for primary CNS lymphoma: initial report of Radiation Therapy Oncology Group (RTOG) protocol 88-06. J Clin Oncol 14: 556-564, 1996. (Pubitemid 26051021)
20. Brada M, Hjiyiannakis D, Hines F, Traish D and Ashley S: Short intensive primary chemotherapy and radiotherapy in sporadic primary CNS lymphoma (PCL). Int J Radiat Oncol Biol Phys 40: 1157-1162, 1998. (Pubitemid 28152932)
21. O'Brien P, Roos D, Pratt G, et al: Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J Clin Oncol 18: 519-526, 2000. (Pubitemid 30078533)
22. Sandor V, Stark-Vanes V, Pearson D, et al: Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma. J Clin Oncol 16: 3000-3006, 1998. (Pubitemid 28417419)
23. Watanabe T, Katayama Y, Yoshino A, Komine C, Yokoyama T and Fukushima T: Long-term remission of primary central nervous system lymphoma by intensified methotrexate chemotherapy. J Neurooncol 63: 87-95, 2003. (Pubitemid 36681648)
24. Herrlinger U, Schabet M, Brugger W, et al: Primary central nervous system lymphoma 1991-1997. Cancer 91: 130-135, 2001.
25. Blay JY, Conroy T, Chevreau C, Thyss A, Quesnel N, Eghbali H, Bouabdallah R, Coiffier B, Wagner JP, Le Mevel A, Dramais-Marcel D, Baumelou E, Chauvin F and Biron P: High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol 16: 864-871, 1998. (Pubitemid 28108718)
26. Bessell EM, Graus F, Lopez-Guillermo A, Villa S, Verger E, Petit J, Holland I and Byrne P: CHOD/BVAM regimen plus radiotherapy in patients with primary CNS non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 50: 457-464, 2001. (Pubitemid 32472275)
27. Yamanaka R, Yajima N, Tsuchiya N, Honma J, Takao T, Morii K, Uzuka T, Takahashi H and Tanaka R: ProMACE-MOPP hybrid protocol in patients with primary CNS lymphoma. Proc Asian Soc Neuro-Oncology: 152, 2002.
28. DeAngelis LM, Seiferheld W, Schold SC, Fisher B and Schultz CJ: Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 20: 4643-4648, 2002. (Pubitemid 36025280)
29. Poortmans PM, Kluin-Nelemans HC, Haaxma-Reiche H, Van't Veer M, Hansen M, Soubeyran P, Taphoorn M, Thomas J, Van den Bent M, Fickers M, Van Imhoff G, Rozewicz C, Teodorovic I and van Glabbeke M: European Organization for Research and Treatment of Cancer Lymphoma Group: High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol 21: 4483-4488, 2003. (Pubitemid 46594017)
30. Neuwelt EA, Goldman DL, Dahlborg SA, Crossen J, Ramsey F, Roman-Goldstein S, Braziel R and Dana B: Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function. J Clin Oncol 9: 1580-1590, 1991.
31. Cher L, Glass J, Harsh GR and Hochberg FH: Therapy of primary CNS lymphoma with methotrexate-based chemotherapy and deferred radiotherapy: preliminary results. Neurology 46: 1757-1759, 1996. (Pubitemid 26185811)
32. Guha-Thakurta N, Damek D, Pollack C, et al: Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: response to therapy and quality of life of patients. J Neurooncol 43: 259-268, 1999. (Pubitemid 29488384)
33. Batchelor T, Carson K, O'Neill A, Grossman SA, Alavi J, New P, Hochberg F and Priet R: Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol 21: 1044-1049, 2003. (Pubitemid 46594133)
34. Herrlinger U, Schabet M, Brugger W, Kortmann RD, Kuker W, Deckert M, Engel C, Schmeck-Lindenau HJ, Mergenthaler HG, Krauseneck P, Benohr C, Meisner C, Wiestler OD, Dichgans J, Kanz L, Bamberg M and Weller M: German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma. Ann Neurol 51: 247-252, 2002. (Pubitemid 34111448)
35. Schlegel U, Pels H, Glasmacher A, Kleinschmidt R, Schmidt-Wolf I, Helmstaedter C, Fliessbach K, Deckert M, Van Roost D, Fimmers R, Bode U and Klockgether T: Combined systemic and intraventricular chemotherapy in primary CNS lymphoma: a pilot study. J Neurol Neurosurg Psychiatry 71: 118-122, 2001.
36. Boiardi A, Silvani A, Valentini S, Salmaggi A, Allegranza A and Broggi G: Chemotherapy as first treatment for primary malignant non-Hodgkin's lymphoma of the central nervous system preliminary data. J Neurol 241: 96-100, 1993. (Pubitemid 23362657)
37. Pels H, Schmidt-Wolf IG, Glasmacher A, Schulz H, Engert A, Diehl V, Zellner A, Schackert G, Reichmann H, Kroschinsky F, Vogt-Schaden M, Egerer G, Bode U, Schaller C, Deckert M, Fimmers R, Helmstaedter C, Atasoy A, Klockgether T and Schlegel U: Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 21: 4489-4495, 2003. (Pubitemid 46594018)
38. Onda K, Wakabayashi K, Tanaka R and Takahashi H: Intracranial malignant lymphomas: clinicopathological study of 26 autopsy cases. Brain Tumor Pathol 16: 29-35, 1999.
39. Ferreri AJ, Reni M, Dell'Oro S, Ciceri F, Bernardi M, Camba L, Ponzoni M, Terreni MR, Tomirotti M, Spina M and Villa E: Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients. Oncology 60: 134-140, 2001. (Pubitemid 32245331)
40. Khan RB, Shi W, Thaler HT, DeAngelis LM and Abrey LE: Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma? J Neurooncol 58: 175-178, 2002. (Pubitemid 34784848)
41. Bleyer WA and Griffin TW: White matter necrosis, mineralizing microangiopathy, and intellectual abilities in survivors of childhood leukemia: associations with central nervous system irradiation and methotrexate therapy. In: Radiation Damage To The Nervous System. A Delayed Therapeutic Hazard. Glibert HA and Kagan AR (eds). Raven, New York, pp155-174, 1980.
42. Reni M, Ferreri AJ and Villa E: Second-line treatment for primary central nervous system lymphoma. Br J Cancer 79: 530-534, 1999. (Pubitemid 29046231)
43. Murray K, Kun L and Cox J: Primary malignant lymphoma of the central nervous system. J Neurosurg 65: 600-607, 1986.
44. Pels H, Schulz H, Manzke O, Hom E, Thall A and Engert A: Intraventricular and intravenous treatment of a patient with refractory primary CNS lymphoma using rituximab. J Neurooncol 59: 213-216, 2002. (Pubitemid 35021571)
45. Reni M, Ferreri AJ, Landoni C and Villa E: Salvage therapy with temozolomide in an immunocompetent patient with primary brain lymphoma. J Natl Cancer Inst 92: 575-576, 2000. (Pubitemid 30212321)
46. Soussain C, Suzan F, Hoang-Xuan K, et al: Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol 19: 742-749, 2001. (Pubitemid 32119089)
47. Abrey LE, Moskowitz CH, Mason WP, Crump M, Stewart D, Forsyth P, Paleologos N, Correa DD, Anderson ND, Caron D, Zelenetz A, Nimer SD and De Angelis LM: Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol 21: 4151-4156, 2003. (Pubitemid 46606183)
48. Yamanaka R, Akutagawa S, Yajima N, Tsuchiya N, Uzuka T, Morii K, Takahashi H, Tanaka R, Saijo N and Nishio K: Selection of surrogate marker genes in primary central nervous system lymphomas to radio-chemotherapy by DNA array analysis of gene expresssion profiles. Int J Oncol 23: 913-923, 2003.